New data show once-weekly insulin icodec met additional endpoints

Danish diabetes care giant Novo Nordisk (NOV: N) on Sunday released positive new data from the Phase IIIa ONWARDS 1 and 3 trials evaluating investigative once-weekly basal insulin icodec at the 83rd Annual Scientific Sessions of the American Diabetes Association (ADA).

The data showed the studies met their primary endpoints, while reducing injections from seven to one per week, compared with once-daily basal insulin. Additionally, data from the ONWARDS 1 and 3 studies demonstrated that more insulin-naïve adults with type 2 diabetes (T2D) treated with once-weekly basal insulin icodec achieved an HbA1c target of <7.0% without experiencing clinically-significant or severe hypoglycemia compared with once-daily basal insulin comparators at 52 and 26 weeks, respectively.

In ONWARDS 1, as a confirmatory secondary endpoint, superior Time in Range (blood glucose 70–180 mg/dL) was achieved with once-weekly basal insulin icodec versus once-daily basal insulin glargine U100 (71.9% versus 66.9%, respectively) from week 48–52. Comparable Time below Range (blood glucose <54 mg/dL) was achieved with once-weekly basal insulin icodec versus once-daily basal insulin glargine U100 (0.3% versus 0.2%, respectively) from week 48–52 in ONWARDS 1. Both values are in line with internationally recommended targets.